Cristhian Espinoza Romero

Dr. Cristhian Espinoza Romero

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 December 2024 in Global Heart
Verified
Journal Article
Open access
MAMurillo Oliveira Antunes
Murillo Oliveira Antunes
FFFabio Fernandes
Fabio Fernandes
EAEdmundo Arteaga-Fernandez
Edmundo Arteaga-Fernandez
FRFélix José Alvarez Ramires
Félix José Alvarez Ramires
VCVinicius Machado Correia
Vinicius Machado Correia
VJVagner Madrini Junior
Vagner Madrini Junior
Sudden cardiac death (SCD) is a major concern in patients with hypertrophic cardiomyopathy (HCM). The American College of Cardiology/American Heart Association (ACC/AHA) and the European Society of Cardiology (ESC) have different guidelines for SCD risk stratification. Their comparative performance in diverse populations remains uncertain. Evaluate the performance of the 2020 ACC/AHA and 2014 ESC guidelines for SCD stratification in a Brazilian cohort with HCM. This retrospective cohort study included patients diagnosed with HCM who were followed in a dedicated clinic at a tertiary hospital in Brazil. The primary outcome was SCD, aborted cardiac arrest due to ventricular fibrillation (VF), sustained ventricular tachycardia (SVT), an episode of VF or SVT, or appropriate ICD therapy. Risk prediction models were assessed using the C-index. A total of 187 patients were included, with a mean follow-up of 8.3 years. The 2020 ACC/AHA guidelines classified 106 (56%) patients as high-risk for SCD, while the 2014 ESC guidelines identified 54 (29%). The primary outcome occurred in 12% of the high-risk group identified by the ACC/AHA guidelines and 13% of the high-risk group identified by the ESC guidelines. Both guidelines showed low discriminatory power for SCD risk in this Brazilian cohort, with AUC values of 0.634 and 0.581 for the ACC/AHA and ESC guidelines, respectively. The 2020 ACC/AHA and 2014 ESC guidelines have limitations in predicting SCD events and defining ICD indications in Brazilian HCM patients. Further studies are needed to refine risk stratification and optimize SCD prevention in this population.

18 December 2023 in PLOS Neglected Tropical Diseases
Verified
Journal Article
Open access
PDF file
EBEdimar Alcides Bocchi
Edimar Alcides Bocchi
GGGuilherme Veiga Guimarães
Guilherme Veiga Guimarães
CRCristhian Espinoza Romero
Cristhian Espinoza Romero
PSPaula Keiko Sato
Paula Keiko Sato
VFVera Lúcia Teixeira de Freitas
Vera Lúcia Teixeira de Freitas
MYMaria Aparecida Shikanai Yasuda
Maria Aparecida Shikanai Yasuda
Chagas disease, endemic in Latin America and spreading globally due to emigration, has a significant health burden, particularly in relation to chagasic heart failure (HF). Chagasic cardiomyopathy (CCM) is characterized by chronic inflammatory myocardial disease. This study aimed to identify inflammatory parameters and biomarkers that could aid in the management of patients with chagasic HF. A cohort study was conducted at a tertiary cardiology single-center over a mean follow-up period of 2.4 years. The study included patients with HF secondary to CCM enrolled between October 2013 and July 2017. Various clinical parameters, echocardiography findings, parasitemia status, brain natriuretic peptide (BNP) and troponin T (TnT) levels, and inflammatory biomarkers (IL-6, IL-10, IL-12p70, IL-17A, adiponectin, and IFN-γ) were assessed. The study encompassed a cohort of 103 patients, with a median age of 53 years and 70% being male. The left ventricular ejection fraction (LVEF) was 28%, with 40% of patients classified as NYHA II functional class. The median BNP level was 291 pg/ml. The observed mortality rate during the study period was 38.8%. Predictors of lower survival were identified as elevated levels of BNP, TnT, reduced LVEF, and increased adiponectin (thresholds: BNP > 309 pg/ml, TnT > 27.5 ng/ml, LVEF < 25.5%, adiponectin > 38 μg/mL). Notably, there was no evidence indicating a relationship between parasitemia and the inflammatory parameters with lower survival in these patients, including INF-γ, IL-6, IL-10, IL12-(p70), and IL17a. Despite the presence of a chronic inflammatory process, the evaluated inflammatory biomarkers in this cohort were not predictive of survival in patients with chagasic HF with reduced ejection fraction (HFrEF). However, reduced LVEF, elevated BNP, adiponectin levels, and troponin T were identified as predictors of lower survival in these patients. Chagas disease, affecting approximately 7 million individuals worldwide, leads to worse outcomes in patients with chagasic cardiomyopathy (CCM) and heart failure with reduced ejection fraction (HFrEF) compared to other etiologies. The chronic inflammatory process associated with Chagas disease is thought to contribute to these adverse outcomes. Inflammatory biomarkers such as TNF-α, IL-6, IL-1β, and angiotensin II are released due to hemodynamic stress in HF and are considered indicators of inflammation. The role of T. cruzi parasitemia in the progression of chagasic cardiomyopathy remains controversial. Additionally, brain natriuretic peptide (BNP) and cardiac troponin are essential biomarkers for assessing mechanical stress and myocardial injury, respectively, due to their prognostic value. However, studies correlating inflammatory biomarkers with prognosis in patients with CCM have yielded conflicting results. In this study, inflammatory biomarkers were not found to be predictors of survival in patients with HFrEF of chagasic etiology. Instead, reduced left ventricular ejection fraction (LVEF), elevated BNP, and TnT levels were identified as strong predictors of lower survival. This suggests that in patients with advanced chagasic heart failure, the role of inflammatory markers in predicting survival may be limited.

28 July 2022 in European Heart Journal - Case Reports
Verified
Journal Article
Open access
PDF file
CRCristhian Espinoza Romero
Cristhian Espinoza Romero
ILIvna Cunha Vieira Lima
Ivna Cunha Vieira Lima
VHViviane Tiemi Hotta
Viviane Tiemi Hotta
EBEdimar Alcides Bocchi
Edimar Alcides Bocchi
VSVera Maria Cury Salemi
Vera Maria Cury Salemi
Background: Endomyocardial fibrosis (EMF) is a rare and underdiagnosed cause of restrictive cardiomyopathy. Its aetiology is not yet defined and could be caused by the influence of different clinical factors that seem to combine with genetic aspects of individuals susceptible to an inflammatory process that leads to formation of fibrosis. Case summary: We describe a case of a 50-year-old man from the northeastern region of Brazil, where there is high prevalence of schistosomiasis. He presented to our centre with symptoms of right heart failure. The echocardiogram showed normal left ventricular ejection fraction. Right ventricular had normal systolic function but in the apical region was filled with a homogeneous and hypoechoic image causing obliteration and restriction of the apex. The late gadolinium enhancement with cardiac magnetic resonance showed diffuse and heterogeneous subendocardial fibrosis in the right ventricle apex consistent with EMF, but declined endocardiectomy. Discussion: This report presents an interesting case of EMF and schistosomiasis simultaneously. The hypothesis of parasitosis as a probable cause of EMF was raised by helminth-induced hypereosinophilia. Complementary imaging tests such as magnetic resonance imaging and echocardiography, in addition to clinical and epidemiological suspicion, are essential for its diagnosis. Early surgical resolution becomes crucial for long-term survival.

9 August 2024 in Journal of Cardiology
Verified
Journal Article
Closed access
CRCristhian Espinoza Romero
Cristhian Espinoza Romero
NPNatalia Melo Pereira
Natalia Melo Pereira
KMKevin De Paula Morales
Kevin De Paula Morales
BBBruno V. Kerges Bueno
Bruno V. Kerges Bueno
GLGeorgina J. Luzuriaga
Georgina J. Luzuriaga
FFFabio Fernandes
Fabio Fernandes

1 March 2025 in ABC Heart Failure & Cardiomyopathy
Verified
Journal Article
Open access
PDF file
CRCristhian Espinoza Romero
Cristhian Espinoza Romero
FFFabio Fernandes
Fabio Fernandes
EMEvandro Tinoco Mesquita
Evandro Tinoco Mesquita
FNFrank Nunes
Frank Nunes
Danon disease is a rare genetic disorder associated with mutations in the LAMP2 gene, located on the X chromosome, which encodes the LAMP2 protein that is essential for autophagy. The disease is characterized by a triad of cardiomyopathy, skeletal myopathy, and intellectual disability, with clinical manifestations that vary between the sexes. Men generally present with more severe and earlier forms, with hypertrophic cardiomyopathy and arrhythmias, whereas women present with later progression and less homogeneous symptoms. To illustrate the wide [...] Abstract Danon disease is a rare genetic disorder associated with mutations in the LAMP2 gene, located on the X chromosome, which encodes the LAMP2 protein that is essential for autophagy. The disease is characterized by a triad of cardiomyopathy, skeletal myopathy, and intellectual disability, with clinical manifestations that vary between the sexes. Men generally present with more severe and earlier forms, with hypertrophic cardiomyopathy and arrhythmias, whereas women present with later progression and less homogeneous symptoms. To illustrate the wide

9 October 2024 in Diagnostics
Verified
Journal Article
Open access
PDF file
CRCristhian Espinoza Romero
Cristhian Espinoza Romero
VRVitor Emer Egypto Rosa
Vitor Emer Egypto Rosa
SKSergio Kormann
Sergio Kormann
BNBryan Nicolalde
Bryan Nicolalde
ALAntonio Sérgio de Santis Andrade Lopes
Antonio Sérgio de Santis Andrade Lopes
RSRoney Orismar Sampaio
Roney Orismar Sampaio
Introduction and objectives: Aortic valve replacement surgery (SAVR) remains a recommended indication, though its pre-surgical stratification is an ongoing challenge. Despite the widespread use of scores like the STS and EuroSCORE II, they have a number of limitations, while often neglecting structural parameters like left ventricular hypertrophy or left atrium volume. This study aimed to evaluate whether a new adaptation of the Généreux classification in the preoperative risk stratification of severe aortic stenosis (AS) is associated with the primary outcome, and to compare it with the original classification versus the traditional scores in short- and long-term follow-up. Methods: We conducted a retrospective, single-center study involving patients with confirmed severe AS who underwent SAVR. The new stratification categorized patients into three stages. Cox regression analyses were conducted to identify factors associated with mortality, with survival analysis performed using Kaplan–Meier curves. A p-value < 0.05 was considered statistically significant. Results: A total of 508 patients were included. Stage 3 patients had a lower median age (67 years). The median EuroSCORE II and STS scores were 2.75 and 2.62%, respectively (p ≤ 0.001). Over a median follow-up of 81 months, 56 deaths occurred (11%). Kaplan–Meier curve analysis revealed significant differences in all-cause mortality among the three groups (HR 4.073, log-rank p ≤ 0.001). Multivariable analysis identified the three preoperative stages (HR 3.22, [95% CI 1.44–7.20], p = 0.004) and mean transaortic gradient (HR 0.96, [95% CI 0.92–0.99], p = 0.021) as independent variables of mortality. The original Généreux scale AUC was higher (AUC: 0.760, 95% CI: 0.692–0.829) compared to the modified Généreux scale (AUC: 0.758, 95% CI: 0.687–0.829). However, no statistical differences were found between the different scales. Conclusions: Preoperative three-stage classification and low transaortic gradient are factors associated with increased all-cause mortality in patients undergoing SAVR. The proposed staging system performed better in the mortality analysis than EuroSCORE II and STS and was similar to the original classification.